Modified FOLFOX6 Chemotherapy in Patients with Metastatic Urachal Cancer

Publisher： Karger

E-ISSN： 1421-9794|59|6|402-406

ISSN： 0009-3157

Source： Chemotherapy, Vol.59, Iss.6, 2014-06, pp. : 402-406

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety and Efficacy of Modified FOLFOX6 plus High-Dose Bevacizumab in Second-Line or Later Treatment of Patients with Metastatic Colorectal Cancer

By  

Chemotherapy, Vol. 59, Iss. 2, 2013-07 ,pp. : 79-84

Karger

Access to resources Recommend Favorite

Safety and Efficacy of Modified FOLFOX6 for Treatment of Metastatic or Locally Advanced Colorectal Cancer

By  

Chemotherapy, Vol. 54, Iss. 5, 2008-09 ,pp. : 395-403

Karger

Access to resources Recommend Favorite

Treatment Outcome and Relevance of Palliative Chemotherapy in Urachal Cancer

By  

Chemotherapy, Vol. 60, Iss. 2, 2014-11 ,pp. : 73-80

Karger

Access to resources Recommend Favorite

Optimal Dose Period for Indisetron Tablets for Preventing Chemotherapy-Induced Nausea and Vomiting with Modified FOLFOX6: A Randomized Pilot Study

By  

Chemotherapy, Vol. 58, Iss. 6, 2013-01 ,pp. : 439-444

Karger

Access to resources Recommend Favorite

A Pilot Study of Oxaliplatin, Fluorouracil and Folinic Acid (FOLFOX-6) as First-Line Chemotherapy in Advanced or Recurrent Gastric Cancer

By  

Chemotherapy, Vol. 54, Iss. 3, 2008-06 ,pp. : 228-235

Karger

Access to resources Recommend Favorite